Gulmez A.Dr.2024-08-042024-08-0420202468-2942https://doi.org/10.1016/j.ctarc.2020.100259https://hdl.handle.net/11616/92022In recent years, serious changes have been observed in the treatment algorithms of especially lung cancer patients. The start-up phase of treatment planning of metastatic lung adenocarcinoma patients is comprised of driver mutation research. Among the pretreatment options of patients diagnosed with EML4-ALK rearrangement, is crizotinib. The group disgnosed with EML4-ALK rearrangement, composes a little part of metastatic non-small cell lung cancer. In this case presented, I will focus on the start of crizotinib treatment and 53-month follow-up in remission in a patient, who has been operated twice and received cisplatin-based adjuvant chemotherapy twice, and relapsed for the second time as Stage-4. © 2020 The Author(s)eninfo:eu-repo/semantics/openAccessCrizotinibEML4-ALKLung cancerArticle253330750810.1016/j.ctarc.2020.1002592-s2.0-85097781629Q3